Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Michael E. Thase
University of Pennsylvania
944Publications
112H-index
54.1kCitations
Publications 944
Newest
Published on Oct 1, 2019in Journal of Affective Disorders 4.08
Vicki Fung16
Estimated H-index: 16
(Harvard University),
Lindsay Overhage (Harvard University)+ 11 AuthorsMichael E. Thase112
Estimated H-index: 112
(UPenn: University of Pennsylvania)
Abstract Background Complex polypharmacy (CP) is common in bipolar disorder (BD). We assessed the associations between CP, adherence, and side effect burden, and patient traits associated with clinical improvement in relationship to CP. Methods We conducted a secondary analysis of 482 adult BD participants in the Bipolar CHOICE trial. We examined the associations between CP (use of ≥3 BD medications) and non-adherence (missing >30% of BD medication doses in the last 30 days) and side effect burd...
Source Cite
Published on Aug 1, 2019in Acta Neuropsychiatrica 1.98
Ole Köhler-Forsberg5
Estimated H-index: 5
,
Louisa G. Sylvia22
Estimated H-index: 22
+ 13 AuthorsTerence A. Ketter67
Estimated H-index: 67
Immune system markers may predict affective disorder treatment response, but whether an overall immune system marker predicts bipolar disorder treatment effect is unclear. Bipolar CHOICE (N = 482) and LiTMUS (N = 283) were similar comparative effectiveness trials treating patients with bipolar disorder for 24 weeks with four different treatment arms (standard-dose lithium, quetiapine, moderate-dose lithium plus optimised personalised treatment (OPT) and OPT without lithium). We performed seconda...
Source Cite
Published on Jul 10, 2019in Expert Opinion on Pharmacotherapy 3.04
Michael E. Thase112
Estimated H-index: 112
(UPenn: University of Pennsylvania),
Peter Zhang5
Estimated H-index: 5
(Princeton University)
+ 2 AuthorsMary Hobart4
Estimated H-index: 4
(Princeton University)
Source Cite
Published on Dec 1, 2018in Behavior Therapy 3.24
Joseph M. Trombello5
Estimated H-index: 5
(UTSW: University of Texas Southwestern Medical Center),
Jeffrey R. Vittengl21
Estimated H-index: 21
(TSU: Truman State University)
+ 3 AuthorsRobin B. Jarrett33
Estimated H-index: 33
(UTSW: University of Texas Southwestern Medical Center)
Abstract Major depressive disorder (MDD) and relationship discord between cohabiting partners frequently co-occur, with bidirectional effects established. As relationship quality influences understanding and treatment of MDD, the current analyses clarified the relations of pretreatment dyadic discord with outcomes during and at the end of acute phase cognitive therapy (CT) for adults with recurrent MDD. Married or cohabiting patients ( n = 219) completed the Dyadic Adjustment Scale (DYS) before ...
1 Citations Source Cite
Published on Dec 1, 2018in Behavior Therapy 3.24
Jeffrey R. Vittengl21
Estimated H-index: 21
(TSU: Truman State University),
Lee Anna Clark68
Estimated H-index: 68
(ND: University of Notre Dame)
+ 1 AuthorsRobin B. Jarrett33
Estimated H-index: 33
Abstract Patients’ beliefs about depression and expectations for treatment can influence outcomes of major depressive disorder (MDD) treatments. We hypothesized that patients with weaker biological beliefs (less endorsement of [a] biochemical causes and [b] need for medication) and more optimistic treatment expectations (greater improvement and shorter time to improvement), have better outcomes in cognitive therapy (CT). Outpatients with recurrent MDD who received acute-phase CT ( N = 152), and ...
Source Cite
Published on Jun 29, 2019in Neuropsychopharmacology 7.16
Michael E. Thase112
Estimated H-index: 112
(UPenn: University of Pennsylvania),
Arielle D. Stanford14
Estimated H-index: 14
(Alkermes)
+ 7 AuthorsSanjeev Pathak (Alkermes)
Buprenorphine/samidorphan (BUP/SAM; ALKS 5461) is an investigational opioid system modulator for the adjunctive treatment of patients with major depressive disorder (MDD), who did not respond adequately to prior antidepressant therapy (ADT). FORWARD-2, an open-label extension study, assessed long-term safety and tolerability of adjunctive BUP/SAM treatment in these patients. Patients from four short-term trials and de novo patients were enrolled; all had confirmed MDD and a current major depress...
Source Cite
Published on Jun 1, 2019in Journal of Psychiatric Research 3.92
Harold A. Sackeim85
Estimated H-index: 85
(Columbia University),
Scott T. Aaronson13
Estimated H-index: 13
(UMB: University of Maryland, Baltimore)
+ 6 AuthorsA. John Rushi (TTU: Texas Tech University)
Abstract There is considerable diversity in how treatment-resistant depression (TRD) is defined. However, every definition incorporates the concept that patients with TRD have not benefited sufficiently from one or more adequate trials of antidepressant treatment. This review examines the issues fundamental to the systematic evaluation of antidepressant treatment adequacy and resistance. These issues include the domains of interventions deemed effective in treatment of major depressive episodes ...
Source Cite
Published on May 21, 2019in American Journal of Psychiatry 13.65
Vanina Popova1
Estimated H-index: 1
,
Ella J. Daly14
Estimated H-index: 14
+ 13 AuthorsRichard C. Shelton56
Estimated H-index: 56
Objective:About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients wi...
1 Citations Source Cite
12345678910